66 GSK Annual Report 2012 Financial review Property, plant and equipment Financial position and resources Our business is science-based, technology-intensive and highly 2012 2011 regulated by governmental authorities.
We allocate significant financial m m resources to the renewal and maintenance of its property, plant and Assets equipment to minimise risks of interruption of production and to Non-current assets achieve compliance with regulatory standards.
A number of its Property, plant and equipment 8,776 8,748 processes use chemicals and hazardous materials.
Goodwill 4,359 3,754 The total cost of our property, plant and equipment at 31 December Other intangible assets 10,161 7,802 2012 was 18,742 million, with a net book value of 8,776 million.
Investments in associates and joint ventures 579 560 Of this, land and buildings represented 4,043 million, plant and Other investments 787 590 equipment 2,854 million and assets in construction 1,879 million.
Deferred tax assets 2,385 2,849 In 2012, we invested 1,165 million in new and renewal property, plant Derivative financial instruments 54 85 and equipment.
This is mainly related to a large number of projects for Other non-current assets 682 525 the renewal, improvement and expansion of facilities at various Total non-current assets 27,783 24,913 worldwide sites.
Property is mainly held freehold.
New investment is nanced from our liquid resources.
At 31 December 2012, we had Current assets capital contractual commitments for future expenditure of 572 million Inventories 3,969 3,873 and operating lease commitments of 849 million.
We believe that our Current tax recoverable 103 85 facilities are adequate for our current needs.
Trade and other receivables 5,242 5,576 We observe stringent procedures and use specialist skills to manage Derivative financial instruments 49 70 environmental risks from these activities.
Environmental issues, Liquid investments 81 184 sometimes dating from operations now modied or discontinued, Cash and cash equivalents 4,184 5,714 are reported under Environmental sustainability on page 54 and Assets held for sale 64 665 in Note 44 to the financial statements, Legal proceedings.
Total current assets 13,692 16,167 Total assets 41,475 41,080 Goodwill Goodwill increased during the year to 4,359 million at December Liabilities 2012, from 3,754 million.
The increase primarily reects the Current liabilities goodwill arising on the acquisition of HGS of 791 million, partly Short-term borrowings 3,631 2,698 offset by a weakening of overseas currencies.
Trade and other payables 8,054 7,359 Derivative financial instruments 63 175 Other intangible assets Current tax payable 1,374 1,643 Other intangible assets include the cost of intangibles acquired from Short-term provisions 693 3,135 third parties and computer software.
The net book value of other Total current liabilities 13,815 15,010 intangible assets as at 31 December 2012 was 10,161 million 2011 7,802 million.
The increase in 2012 reected assets Non-current liabilities acquired from the acquisition of HGS of 1,249 million and from Long-term borrowings 14,671 12,203 the acquisition of the global rights to the Shionogi ViiV Healthcare Deferred tax liabilities 1,004 822 LLC joint venture assets of 1,777 million, partly offset by the Pensions and other post-employment benets 3,105 3,091 amortisation and impairment of existing intangibles.
Other provisions 699 499 Derivative financial instruments 2 2 Investments Other non-current liabilities 1,432 626 We held investments, including associates and joint ventures, Total non-current liabilities 20,913 17,243 with a carrying value at 31 December 2012 of 1,366 million Total liabilities 34,728 32,253 2011 1,150 million.
The market value at 31 December 2012 Net assets 6,747 8,827 was 1,968 million 2011 1,355 million.
The largest of these investments are in an associate, Aspen Pharmacare Holdings Limited, Equity which had a book value at 31 December 2012 of 430 million Share capital 1,349 1,387 2011 393 million and an investment in Theravance, Inc. Share premium account 2,022 1,673 which had a book value at 31 December 2012 of 362 million Retained earnings 652 3,370 2011 226 million.
The investments include equity stakes in Other reserves 1,787 1,602 companies where the Group has research collaborations, which Shareholders equity 5,810 8,032 provide access to biotechnology developments of potential interest Non-controlling interests 937 795 and interests in companies that arise from business divestments.
Total equity 6,747 8,827 2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 67 Derivative financial instruments: assets Net debt We had both non-current and current derivative financial 2012 2011 instruments held at fair value of 103 million 2011 155 million.
m m The majority of this amount relates to interest rate swaps and Cash, cash equivalents and foreign exchange contracts designated as accounting hedges.
liquid investments 4,265 5,898 Borrowings repayable within one year 3,631 2,698 Inventories Borrowings repayable after one year 14,671 12,203 Inventory of 3,969 million has increased by 96 million during the Net debt 14,037 9,003 year.
The increase reects the impact of the acquisition of HGS Net debt increased by 5,034 million and reected the acquisition together with higher Vaccine stocks, partly offset by initiatives to of HGS for 2,031 million, net of cash acquired, together with reduce manufacturing cycle times and reduce stockholding days the legal settlements in the year of 2,610 million which included through more efficient use of inventory throughout the supply chain.
the previously announced payments to the US Government of 1.9 billion $3 billion in settlement of certain investigations.
Trade and other receivables The Groups strong cash generation together with the proceeds Trade and other receivables of 5,242 million have decreased from from the disposal of the Consumer Healthcare OTC brands also 2011 reecting specic actions taken to reduce overdue and other enabled the nancing of share repurchases of 2.5 billion and receivables as part of our initiative to reduce working capital.
increased dividend payments of 3.8 billion.
Derivative financial instruments: liabilities Movements in net debt We held current and non-current derivative financial instruments held at fair value of 65 million 2011 177 million relating 2012 2011 m m primarily to foreign exchange contracts which represent hedges Net debt at beginning of year 9,003 8,859 of inter-company loans and deposits, external debt and legal provisions, but are not designated as accounting hedges.
Decrease in cash and bank overdrafts 1,607 94 Cash inow from liquid investments 224 30 Trade and other payables Net increase in long-term loans 4,430 Trade and other payables amounting to 8,054 million have Net repayment of increase in short-term loans 816 37 increased from 7,359 million in 2011, reecting the amount Debt of subsidiary undertakings acquired 3 10 payable to non-controlling shareholders in GSK Consumer Exchange movements 385 10 Healthcare Ltd. in India under the offer to purchase additional Other movements 29 37 shares and also the benets of our working capital initiatives.
Net debt at end of year 14,037 9,003 Provisions Total equity We carried deferred tax provisions and other short-term and At 31 December 2012, total equity had decreased from 8,827 non-current provisions of 2,396 million at 31 December 2012 million at 31 December 2011 to 6,747 million.
The decrease arose 2011 4,456 million in respect of estimated future liabilities, of principally from share repurchases in the year.
which 527 million 2011 2,772 million related to legal and other disputes.
Provision has been made for legal and other disputes, A summary of the movements in equity is set out below.
indemnified disposal liabilities, employee related liabilities and the 2012 2011 costs of restructuring programmes to the extent that at the balance m m sheet date a legal or constructive obligation existed and could be Total equity at beginning of year 8,827 9,745 reliably estimated.
Total comprehensive income for the year 4,011 4,424 Pensions and other post-employment benets Dividends to shareholders 3,814 3,406 Shares issued 356 250 We account for pension and other post-employment Changes in non-controlling interests 218 18 arrangements in accordance with IAS 19.
The deficits, net of Forward contract relating to non-controlling surpluses before allowing for deferred taxation were 1,313 million interest 8 29 2011 1,476 million on pension arrangements and 1,668 million Shares purchased and cancelled or held 2011 1,595 million on unfunded post-employment liabilities.
as Treasury shares 2,493 2,191 The pension liabilities decreased following an increase in asset Consideration received for shares transferred values in the UK, deficit reduction contributions of 368 million by ESOP Trusts 58 45 2011 450 million and the one-off adjustments to the UK Shares acquired by ESOP Trusts 37 36 pension obligations made during the year, partly offset by reductions Share-based incentive plans 211 191 in the rates used to discount UK pension liabilities from 4.8% to 4.4% and US pension liabilities from 4.4% to 3.8%.
Tax on share-based incentive plans 9 50 Distributions to non-controlling interests 171 234 In December 2010, the UK scheme purchased an insurance contract Total equity at end of year 6,747 8,827 that will guarantee payment of specified pensioner liabilities.
This contract was valued at 751 million at 31 December 2012.
The changes in non-controlling interests in the year primarily arise from the acquisitions of the Shionogi-ViiV Healthcare joint venture and further shares in GSK Consumer Healthcare Ltd, the Groups Consumer Healthcare subsidiary in India.
68 GSK Annual Report 2012 Financial review Commitments in respect of loans and future interest payable Share purchases on loans are disclosed before taking into account the effect In 2012, the Employee Share Ownership Plan ESOP Trusts acquired of derivatives.
37 million of shares in GlaxoSmithKline plc 2011 36 million.
We have entered into a number of research collaborations to Shares are held by the Trusts to satisfy future exercises of options develop new compounds with other pharmaceutical companies.
and awards under the Group share option and award schemes.
A The terms of these arrangements can include upfront fees, equity proportion of the shares held by the Trusts are in respect of awards investments, loans and commitments to fund specified levels of where the rules of the scheme require us to satisfy exercises through research.
In addition, we will often agree to make further payments market purchases rather than the issue of new shares.
The shares if future milestones are achieved.
held by the Trusts are matched to options and awards granted.
As some of these agreements relate to compounds in the early At 31 December 2012, the ESOP Trusts held 75 million 2011 stages of development, milestone payments will continue for a 91 million GSK shares against the future exercise of share options number of years if the compounds move successfully through the and share awards.
The carrying value of 391 million 2011 development process.
Generally the closer the product is to 492 million has been deducted from other reserves.
The market marketing approval the greater the possibility of success.
The value of these shares was 1,004 million 2011 1,337 million.
amounts shown above within intangible assets represent the During 2011, we commenced a new long-term share buy-back maximum that would be paid if all milestones were achieved, and programme.
174 million shares were repurchased in 2012 at a cost include 6.0 billion which relates to externalised projects in the of 2,493 million see Note 33 Share capital.
We are currently discovery portfolio.
A number of new commitments were made in targetting further repurchases of 1-2 billion during 2013.
The 2012 under licensing and other agreements, including arrangements exact amount and timing of future purchases, and whether the with Angiochem, Inc. Five Prime Therapuetics, Inc. MD Anderson shares will be held as Treasury shares or be cancelled, will be Cancer Centre and Morphotek, Inc. determined by the company and is dependent on market conditions In 2009, we reached an agreement with the trustees of the UK and other factors.
At 31 December 2012, we held 495 million pension schemes to make additional contributions over a five shares as Treasury shares 2011 501.2 million shares, at a cost of year period, to eliminate the pension deficit identied at the 6,602 million 2011 6,661 million, which has been deducted 31 December 2008 actuarial funding valuation.
The table above from retained earnings.
includes this commitment but excludes the normal ongoing annual No shares were purchased in the period 1 January 2013 to funding requirement in the UK of approximately 120 million.
For further information on pension obligations, see Note 28 to the financial statements, Pensions and other post-employment Commitments and contingent liabilities benets.
Financial commitments are summarised in Note 39 to the financial Contingent liabilities statements, Commitments.
Other contingent liabilities and obligations in respect of short and long-term debt are set out in The following table sets out contingent liabilities, comprising Note 31 to the financial statements, Contingent liabilities and discounted bills, performance guarantees, letters of credit and other Note 32 to the financial statements, Net debt.
items arising in the normal course of business, and when they are expected to expire.
Amounts provided for pensions and post-retirement benets are set out in Note 28 to the financial statements, Pensions and other Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs post-employment benets.
Amounts provided for restructuring m m m m m programmes and legal, environmental and other disputes are set Guarantees 132 79 3 1 49 out in Note 29 to the financial statements, Other provisions.
Other contingent liabilities 77 3 41 17 16 Total 209 82 44 18 65 Contractual obligations and commitments The following table sets out our contractual obligations and In the normal course of business, we have provided various commitments at 31 December 2012 as they fall due for payment.
indemnification guarantees in respect of business disposals in which legal and other disputes have subsequently arisen.
Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs A provision is made where an outow of resources is considered m m m m m probable and a reliable estimate can be made of the likely outcome Loans 18,302 3,607 2,834 2,243 9,618 of the dispute and this is included in Note 29 to the financial Interest on loans 10,207 690 1,243 1,107 7,167 statements, Other provisions.
Finance lease obligations 76 27 34 10 5 We provide for the outcome of tax, legal and other disputes when Finance lease charges 9 3 4 1 1 an outow of resources is considered probable and a reliable Operating lease estimate of the outow may be made.
At 31 December 2012, other commitments 849 146 175 115 413 than for those disputes where provision has been made, it was not Intangible assets 7,780 551 889 1,365 4,975 possible to make a reliable estimate of the potential outow of Property, plant & equipment 572 473 99 funds that might be required to settle disputes where the possibility Investments 72 19 32 21 of there being an outow was more than remote.
Purchase commitments 762 209 293 260 The ultimate liability for such matters may vary signicantly from Pensions 368 368 the amounts provided and is dependent upon the outcome of Other commitments 268 90 109 67 2 litigation proceedings and negotiations with the relevant tax Total 39,265 6,183 5,712 5,189 22,181 authorities.
This is discussed further in Risk factors on pages 78 to 86 and Notes 14 and 44 to the financial statements, Taxation and Legal proceedings.
2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 69 A reconciliation of net cash inow from operating activities, which is Cash generation and conversion the closest equivalent IFRS measure, to free cash ow is shown below.
A summary of the consolidated cash ow is set out below.
Reconciliation of free cash ow 2012 2011 m m 2012 2011 Net cash inow from operating activities 4,375 6,250 m m Net cash outow from investing activities 2,631 112 Net cash inow from operating activities 4,375 6,250 Net cash outow from nancing activities 3,351 6,232 Purchase of property, plant and equipment 1,051 923 Decrease in cash and bank overdrafts 1,607 94 Purchase of intangible assets 469 405 Disposal of property, plant and equipment 68 100 Exchange adjustments 92 108 Interest paid 779 769 Cash and bank overdrafts at beginning of year 5,605 5,807 Interest received 30 97 Cash and bank overdrafts at end of year 3,906 5,605 Dividends received from joint ventures and Cash and bank overdrafts at end of year associated undertakings 46 25 comprise: Distributions to non-controlling interests 171 234 Cash and cash equivalents 4,184 5,714 Free cash ow 2,049 4,141 Overdrafts 278 109 Investment appraisal 3,906 5,605 We have a formal process for assessing potential investment The net cash inow from operating activities after taxation paid was proposals in order to ensure decisions are aligned with our overall 4,375 million, a decrease of 1,875 million in sterling terms strategy.
This process includes an assessment of the cash ow return compared with 2011 and reected the impact of a reduced on investment CFROI, as well as its net present value NPV and operating profit and the phasing of tax payments.
internal rate of return IRR where the timeline for the project is very The net cash outow from investing activities was 2,631 million, long term.
We also consider the impact on earnings and credit 2,519 million higher than 2011, which primarily reected the prole where relevant.
acquisition of HGS and the sale of the non-core OTC brands during The discount rate used to perform financial analyses is decided the year, partly offset by the proceeds from the disposal of our internally, to allow determination of the extent to which investments shareholding in Quest Diagnostics Inc. during 2011. cover our cost of capital.
For specic investments the discount rate The net cash outow from nancing activities was 3,351 million may be adjusted to take into account country or other risk weightings.
and primarily reected a net increase in external borrowing of Capital expenditure and financial investment 3,614 million offset by the repurchase of shares and dividends to shareholders totalling 6,307 million.
Cash payments for tangible and intangible xed assets amounted to 1,520 million 2011 - 1,328 million and disposals realised Free cash ow 1,124 million 2011 337 million.
Cash payments to acquire equity investments of 229 million 2011 76 million were made Free cash ow is the amount of cash generated by the business in the year and sales of equity investments realised 28 million after meeting its obligations for interest, tax and dividends paid to 2011 68 million.
non-controlling interests, and after capital expenditure on property, plant and equipment and intangible assets.
Future cash ow 2012 2011 We expect that future operating cash ow will be sufficient to fund Free cash ow m 2,049 4,141 our operating and debt service costs, to satisfy normal levels of Free cash ow growth % 51 % 8 % capital expenditure, to meet obligations under existing licensing Free cash ow was adversely impacted by legal settlements of agreements, to meet the expenditure arising from the major 2,610 million 2011 1,466 million.
Free cash ow excluding legal restructuring programmes the precise timing of which is uncertain settlements was 4,659 million in 2012 2011 5,607 million, and outlined in Note 10 to the financial statements, Major restructuring this, together with 904 million from the disposal of the non-core costs and to meet other routine outows including tax and OTC brands, enabled the Group to pay dividends to shareholders of dividends, subject to the Risk factors discussed on pages 78 to 86.
3.8 billion, and spend 2.5 billion on repurchasing shares.
We may from time to time have additional demands for finance, such as for acquisitions and share repurchases.
We have access to Our commitment is to continue to use free cash ow to support other sources of liquidity from short and long-term capital markets increasing dividends, undertake share repurchases or, where returns are and banks and other financial institutions, in addition to the cash more attractive, reinvest in the business, including bolt-on acquisitions.
ow from operations, for such needs.
Working capital 2011 2012 restated Working capital percentage of turnover % 21% 21% Working capital conversion cycle days 194 202 Working capital reduced by 397 million in 2012 compared with a reduction of 477 million in 2011.
Working capital conversion cycle reduced by eight days reecting improvements in conversion for receivables, payables and inventory.
This was partly offset by the acquisition of HGS, which added three days to the conversion cycle.
70 GSK Annual Report 2012 Financial review Maturity profile of gross debt m equivalent 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 2013 2014 2015 2017 2018 2022 2025 2027 2033 2034 2038 2039 2042 2045 GBP bonds EUR bonds USD bonds Commercial Paper Other bank borrowings Leases Payment policies Capital management Group companies are responsible for monitoring and managing their Our financial strategy supports the Groups strategic priorities and it working capital.
The terms of sales collections and supplier is regularly reviewed by the Board.
We manage the capital structure payments reect local commercial practice.
of the Group through an appropriate mix of debt and equity in order to optimise returns to shareholders whilst maintaining credit ratings In the UK, the company and each of its UK subsidiaries have policies that provide us with exibility to access debt capital markets on to ensure that suppliers are paid on time.
Our financial architecture is designed to drive the UK companies seek: growth in earnings per share and cash generation in order to s to settle terms of payment with suppliers when agreeing the maximise the returns from the Groups strategy.
The free cash ow terms of the transaction we generate is then deployed to deliver returns to shareholders and reinvested in the business depending on where returns are most s to ensure that suppliers are made aware of the agreed terms attractive.
We continue to apply strict financial and returns-based of payment criteria such as cash ow return on investment in order to allocate s to abide by the terms of payment.
capital and assess investment opportunities.
The policy permits arrangements for accelerated payment to small The capital structure of the Group consists of net debt of suppliers.
14.0 billion see Note 32, Net debt and shareholders equity of 5.8 billion see Consolidated statement of changes in equity on Payment performance page 142.
Total capital, including that provided by non-controlling interests of 0.9 billion, is 20.7 billion.
At 31 December 2012, the average number of days payable outstanding represented by trade payables of the parent company For further details see Note 41 to the financial statements Financial was nil 2011 nil and in respect of the company and its UK instruments and related disclosures.
subsidiaries in aggregate was 56 days 2011 61 days.
Liquidity Treasury policies As at 31 December 2012, our cash and liquid investments were held GSK reports in Sterling and pays dividends out of Sterling profits.
as follows: The role of Corporate Treasury is to monitor and manage our external 2012 2011 and internal funding requirements and financial risks in support of m m our strategic objectives.
GSK operates on a global basis, primarily Bank balances and deposits 3,456 3,875 through subsidiary companies, and we manage our capital to ensure US Treasury and Treasury repo that our subsidiaries are able to operate as going concerns and to only money market funds 728 1,839 optimise returns to shareholders through an appropriate balance of Corporate debt instruments 7 9 debt and equity.
Treasury activities are governed by policies and procedures approved by the Board of Directors, most recently on Government securities 74 175 11 July 2012.
A Treasury Management Group TMG meeting chaired 4,265 5,898 by our Chief Financial officer, takes place on a monthly basis to review treasury activities.
Its members receive management information relating to treasury activities.
2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 71 We had net debt of 14.0 billion at 31 December 2012.
The table below Interest rate risk management summarises cash and gross debt after the effects of hedging.
GSKs objective is to reduce our effective net interest cost and to rebalance the mix of debt at xed and oating interest rates over 2012 2011 m m time.
The policy on interest rate risk management limits the amount Cash and liquid investments 4,265 5,898 of oating interest payments to a prescribed percentage of operating profit.
Gross debt xed 15,205 13,621 oating 3,090 1,279 We use a series of interest rate swaps to redenominate one of non-interest bearing 7 1 our bonds into oating interest rates.
The duration of these swaps Net debt 14,037 9,003 matches the duration of the principal instrument.
These interest rate derivative instruments are accounted for as fair value hedges of GSKs policy is to borrow centrally in order to meet anticipated the relevant liability.
The cash ow forecast and funding requirements are monitored by the TMG on a monthly basis.
Foreign exchange risk management Our strategy is to diversify liquidity sources using a range of facilities and to maintain broad access to funding markets.
Foreign currency transaction exposures arising on internal and external trade ows are not hedged.
The exposure of overseas At 31 December 2012, GSK had 4.3 billion of cash, cash equivalents operating subsidiaries to transaction risk is minimised by matching and liquid investments and 3.6 billion of borrowings repayable local currency income with local currency costs.
For this purpose, our within one year.
GSK also has access to short-term finance under internal trading transactions are matched centrally and we manage a US$10 billion commercial paper programme and $2.9 billion inter-company payment terms to reduce foreign currency risk.
1.7 billion was in issue under this programme at 31 December Foreign currency cash ows can be hedged selectively under the 2012.
GSK has 1.9 billion five year committed medium term management of Corporate Treasury and the TMG.
Where possible, facilities and $2.5 billion of 364-day committed facilities.
These we manage the cash surpluses or borrowing requirements of facilities were put in place in September 2012.
We consider this subsidiary companies centrally using forward contracts to hedge level of committed facilities to be adequate given current liquidity future repayments back into the originating currency.
In order to reduce foreign currency translation exposure, we seek to We have a European Medium Term Note programme of 15 billion denominate borrowings in the currencies of our principal assets and and at 31 December 2012, 7.0 billion of notes were in issue under cash ows.
These are primarily denominated in US dollars, Euros and this programme.
We also have a US shelf registration statement and Sterling.
Certain borrowings can be swapped into other currencies at 31 December 2012, we had $15.0 billion 9.2 billion of notes in as required.
GSKs long-term borrowings mature at dates between 2014 and 2045.
Borrowings denominated in, or swapped into, foreign currencies that match investments in overseas Group assets may be treated GSKs long-term credit ratings have remained unchanged since as a hedge against the relevant assets.
Forward contracts in major February 2008 and currently GSK is rated A stable outlook by currencies are also used to reduce our exposure to our investment Standard and Poors and A1 stable outlook by Moodys Investors in overseas Group assets.
The TMG reviews the ratio of borrowings Service Moodys.
Our short-term credit ratings are A-1 and P-1 to assets for major currencies monthly.
with Standard and Poors and Moodys respectively.
Counterparty risk management Treasury operations GSK sets global counterparty limits for each of GSKs banking and The objective of treasury activity is to manage the post-tax net cost investment counterparties based on long-term credit ratings from or income of financial operations to the benefit of earnings.
We use Moodys and Standard and Poors.
Corporate Treasurys usage of a variety of financial instruments to finance our operations and these limits is monitored daily by a Corporate Compliance officer derivative financial instruments to manage market risks from these CCO who operates independently of Corporate Treasury.
These derivatives, principally comprising forward foreign breach of these limits would be reported to the CFO immediately.
currency contracts, interest rate and currency swaps, are used to The CCO also monitors the credit rating of these counterparties and, swap borrowings and liquid assets into currencies required for when changes in ratings occur, noties Corporate Treasury so that Group purposes and to manage exposure to financial risks from changes can be made to investment levels or to authority limits as changes in foreign exchange and interest rates.
In addition, a report on relationship banks and their Corporate Treasury does not operate as a profit centre.
We do not credit ratings is presented annually to the TMG for approval and hold or issue derivatives for speculative purposes.
policies specically prohibit such activity.
All transactions in financial instruments are undertaken to manage the risks arising from underlying business activities, not for speculation.
